Novel Osteobiologic Proteins for Treatment of Osteoporosis, Rheumatoid and Neurologic Diseases
Posted Jul 26 2011 8:00pm
Description of Invention: In an effort to find effective strategies for treatment of body tissue and structural damage as the result of trauma, cancer and other diseases, scientists at the Food and Drug Administration (FDA) have identified Cartilage-Derived Morphogenetic Proteins (CDMP) and associated pathways instrumental in replacing or regenerating damaged tissue. These proteins have unique activities likely to be useful as stand alone agents or in construction of engineered tissues.
CDMPs appear helpful in the healing of bone and joint surface lesions, and also for the repair or reconstruction of cartilaginous tissues, tendons and ligaments. The invention identifies proteins belonging to TGF-Beta superfamily that promote repair of menisci, cruciate and collateral ligaments of the knee, and rotator cuff tendons. The patent application claims nucleic acids encoding human Cartilage-Derived Morphogenetic Protein-1 (hCDMP-1) variant polypeptides. Morphogenetic proteins are able to induce the proliferation and differentiation of progenitor cells into functional bone, cartilage, tendon, or ligament tissue.
rheumatic diseases of the bone
osteoporosis and osteoarthritis
growth and repair of musculoskeletal tissues
Advantages: Osteobiologics, such as CDMPs, have the ability to stimulate musculo-skeletal repair instead of using donated human tissue allografts and synthetic materials.
Development Status: Early stage
Inventors: Malcolm C Moos (FDA) John T Thomas (FDA)
For Licensing Information Please Contact: Surekha Vathyam Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4076 Fax: 301-402-0220